Advice
following a full submission:
ritlecitinib (Litfulo®) is accepted for use within NHSScotland.
Indication under review: For the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.
In a randomised, double-blind, phase IIb/III study in patients with severe alopecia areata, ritlecitinib was associated with statistically significant improvements in scalp hair regrowth versus placebo at week 24.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- ritlecitinib (Litfulo)
- SMC ID:
- SMC2610
- Indication:
Treatment of severe alopecia areata in adults and adolescents aged 12 years and over.
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Skin
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 08 April 2024